Welcome to our dedicated page for TCGX Acquisition SEC filings (Ticker: TCGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TCGX Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TCGX Acquisition's regulatory disclosures and financial reporting.
TCGX Acquisition Corp. (TCGX), a Cayman Islands blank check company, reported its first results for the period from May 26, 2026 (inception) through June 30, 2026, focused on formation and IPO preparation with no operating revenues and a net loss of $67,614 from formation, general and administrative costs. At June 30, 2026 the company had total assets of $253,176, all in prepaid expenses and deferred offering costs, against current liabilities of $295,790 and a working capital deficit of $288,997, funded primarily by a $43,395 related-party promissory note and sponsor-paid expenses.
Subsequent to quarter end, TCGX completed its IPO on August 6, 2026, selling 8,625,000 Class A shares at $10.00 for $86,250,000 of gross proceeds and a concurrent private placement of 522,500 shares for $5,225,000. $86,250,000 was deposited into a Trust Account, with total transaction costs of $5,837,054. The company also entered into a $20,000,000 forward purchase agreement and has a 24‑month “Completion Window” after the IPO closing to complete a business combination, with standard SPAC shareholder redemption rights tied to the Trust Account balance.
TCGX Acquisition Corp. (TCGX) is reported to have 500,000 Class A ordinary shares held by RA Capital Healthcare Fund, L.P., representing 5.5% of the Class A shares. This ownership percentage is based on 9,147,500 Class A ordinary shares outstanding as of August 6, 2026.
RA Capital Management, L.P. serves as investment adviser to the Fund and has been delegated the sole power to vote and dispose of the Fund’s TCGX shares. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners for Section 13(d) purposes but each disclaims beneficial ownership other than for determining reporting obligations.
TCGX Acquisition Corp. (TCGX), a Cayman Islands blank check company focused on healthcare (especially life sciences and medtech, including potential targets in China), is conducting an IPO of 7,500,000 Class A ordinary shares at $10.00 per share, for $75,000,000 in gross proceeds. The underwriters have a 45‑day option to buy up to 1,125,000 additional shares.
$75,000,000 (or $86,250,000 with the over‑allotment) plus private placement proceeds will be placed in a U.S. trust account at $10.00 per share. Public holders can redeem in connection with the initial business combination or certain extensions, generally at trust value per share, but any holder (together with affiliates and group members) is limited to redeeming more than 15% of IPO shares without consent. If no business combination is completed within 24 months (subject to shareholder‑approved extensions), TCGX will liquidate and redeem public shares.
The sponsor and underwriters will buy 500,000 private placement shares at $10.00 (up to 522,500 with over‑allotment), and the sponsor and insiders already hold 2,156,250 Class B founder shares bought for $25,000, designed to represent 20% of post‑IPO shares (excluding private placement). Founder shares convert into Class A on at least a one‑for‑one basis with anti‑dilution protection, creating potential material dilution for public investors. A forward purchase agreement with Fund III commits a minimum of 2,000,000 additional Class A shares at $10.00 at business‑combination closing, subject to Fund III investment committee approval.